Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Women are most likely to experience serious pain following knee replacement than men

Women are most likely to experience serious pain following knee replacement than men

Clinipace Worldwide closes merger with Choice Pharma

Clinipace Worldwide closes merger with Choice Pharma

Total joint replacement may reduce risk for cardiac events and boost long-term survival

Total joint replacement may reduce risk for cardiac events and boost long-term survival

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

Family CV history indicates intensive treatment need for hypertensive patients

Family CV history indicates intensive treatment need for hypertensive patients

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Findings provide new target for development of novel therapies to manage chronic pain

Findings provide new target for development of novel therapies to manage chronic pain

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Research to identify exact mechanisms behind preterm birth and fetal brain injury

Research to identify exact mechanisms behind preterm birth and fetal brain injury

Scientists discover fundamental aggravating factor in autoimmune diseases

Scientists discover fundamental aggravating factor in autoimmune diseases

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Minimally invasive surgery outcomes show favorable results in low back pain patients

Minimally invasive surgery outcomes show favorable results in low back pain patients

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

forMD launches private online community for alumni of Hospital for Special Surgery

forMD launches private online community for alumni of Hospital for Special Surgery

Simple approach best for blood pressure risk stratification

Simple approach best for blood pressure risk stratification

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.